Celltex Therapeutics is reporting that its novel stem cell therapy to treat multiple sclerosis (MS) continues to bear positive results for patients with the disease, having recently released an individual testimony of an MS patient who received the therapy.
The Houston-based company offers regenerative medicine-based therapies by isolating, multiplying and storing adult adipose-derived mesenchymal stem cells (MSCs), which are multi potent stromal cells that can differentiate into several types of cells for autologous use by clinicians.
Multiple sclerosis (MS) is estimated to affect more than 2.3 million individuals in the world, and 400,000 in the U.S. alone. MS is a chronic neurodegenerative disease in which the immune system attacks the healthy central nervous system of an individual, and although not fatal it can become highly disabling since it affects vision and mobility and in more serious cases causes paralysis of an individual.
There is no cure for MS, but Celltex believes it can leverage its technology to improve the quality of life of patients suffering from injuries or vascular, degenerative and autoimmune diseases such as multiple sclerosis. The isolation process of MSCs from the patient begins with the extraction of a small thumb-sized amount of abdominal fat. These MSCs are then isolated from the fat, cultured and stored cryogenically for future use. The patient can use his or her banked stem cells for regenerative therapy through infusions or injections performed by a licensed clinician.
Debbie Bertrand, a Texas native, is telling her story about receiving stem cell therapy using cells from Celltex. In 2001, Bertrand was diagnosed with MS after having symptoms of unresponsiveness in her hands and feet and was discouraged by the scarce available treatment for progressive forms of MS. Bertrand decided to get in touch with Dr. Stanley Jones and learn more about stem cell therapy and Celltex Therapeutics’ services, after being refused to participate in four different clinical trials.
Ten years after Bertrand’s MS diagnosis, she received the first round of adult stem cell infusion. Just after Bertrand performed the stem cell therapy, she noticed a significant increase in her strength and energy and, notably, 9 months after the first treatment, she left her wheelchair and started walking with a walker. In addition, she does not need daily injections to treat her MS.
Debbie Bertrand said in the news release that there were no adverse events after receiving the therapy. She added that she continues to take one oral drug for multiple sclerosis, but for the last four years she has not taken daily injections for MS. She hopes that others in her situation may have the same opportunity to receive this type of treatment. Her third round of stem cell infusions will occur next May at Hospital Galenia, Cancun, Mexico.